- 抑制劑
- 研究領(lǐng)域
- PI3K/Akt/mTOR信號(hào)通路
- 表觀遺傳
- 甲基化
- 免疫&炎癥
- 酪氨酸蛋白激酶
- 血管生成
- 凋亡
- 自噬
- 內(nèi)質(zhì)網(wǎng)應(yīng)激&UPR響應(yīng)
- JAK/STAT信號(hào)通路
- MAPK信號(hào)通路
- 細(xì)胞骨架
- 細(xì)胞周期
- TGF-beta/Smad信號(hào)通路
- DNA損傷/DNA修復(fù)
- 化合物庫(kù)
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲(chǔ)液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 動(dòng)物實(shí)驗(yàn)
- 鼠尾直接PCR試劑盒(快速基因型鑒定)
- 小鼠CD3+ T細(xì)胞分選試劑盒
- 小鼠CD4+ T細(xì)胞分選試劑盒
- 小鼠CD8+ T細(xì)胞分選試劑盒
- 新產(chǎn)品
- 聯(lián)系我們
Idelalisib (CAL-101)
別名: GS-1101 中文名稱：艾代拉里斯，艾代拉利司
Idelalisib (CAL-101)是選擇性p110δ抑制劑，在無(wú)細(xì)胞試驗(yàn)中IC50為 2.5 nM；對(duì) p110δ 表現(xiàn)出的選擇性是對(duì) p110α/β/γ 的 40 到 300 倍，對(duì)p110δ的選擇性是對(duì) C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 還可誘導(dǎo)自噬。
Idelalisib (CAL-101) Chemical Structure
CAS: 870281-82-6
產(chǎn)品質(zhì)控
批次：
純度：
99.93%
99.93
Idelalisib (CAL-101)相關(guān)產(chǎn)品
相關(guān)信號(hào)通路圖
細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例
| 細(xì)胞系 | 實(shí)驗(yàn)類型 | 給藥濃度 | 孵育時(shí)間 | 活性描述 | 文獻(xiàn)信息 |
|---|---|---|---|---|---|
| SR786 | Growth Inhibition Assay | 10 μM | 72 h | does not induce apoptosis | 22801959 |
| Myla | Growth Inhibition Assay | 10 μM | 72 h | does not induce apoptosis | 22801959 |
| HH | Growth Inhibition Assay | 10 μM | 72 h | Induction of apoptosis slightly | 22801959 |
| SP53 | Growth Inhibition Assay | 0.1 μM | 72 h | does not induce cell cycle arrest or apoptosis | 23676220 |
| MINO | Growth Inhibition Assay | 5 μM | 72 h | does not induce cell cycle arrest or apoptosis | 23676220 |
| MAVER-1 | Growth Inhibition Assay | 5 μM | 72 h | does not induce cell cycle arrest or apoptosis | 23676220 |
| JEKO-1 | Growth Inhibition Assay | 5 μM | 72 h | does not induce cell cycle arrest or apoptosis | 23676220 |
| JEKO-1 | Growth Inhibition Assay | 10 μM | 72 h | Inhibition of proliferation slightly | 23341541 |
| Granta-519 | Function Assay | 1 μM | 2 h | Inhibition of Akt(s473) phosphorylation | 23341541 |
| Granta-519 | Function Assay | 1 μM | 2 h | Inhibition of Akt(t308) phosphorylation | 23341541 |
| JEKO-1 | Function Assay | 1 μM | 72 h | Inhibition of Akt phosphorylation in IgM-stimulated JEKO-1 | 23341541 |
| Primary CLL cell | Function Assay | 1 μM | 15 min | Blocks BCR-induced LCP1 serine-5 activation | 24009233 |
| Microglia | Function Assay | 5 μM | 10 h | Decrease of TNFa secretion from LPS-stimulated p110δD910A/D910A microglia | 24625684 |
| Primary AML cell | Growth Inhibition Assay | 1 μM | 3 h | Suppression of rRNA synthesis | 25014775 |
| Primary AML cell | Function Assay | 1 μM | 3 h | Inhibition of GSK3 phosphorylation | 25014775 |
| Primary AML cell | Function Assay | 1 μM | 3 h | Inhibition of P70S6K phosphorylation | 25014775 |
| Primary AML cell | Function Assay | 1 μM | 3 h | Inhibition of Akt phosphorylation | 25014775 |
| K562 | Growth Inhibition Assay | 1 μM | 72 h | Inhibition of proliferation | 25014775 |
| K562 | Function Assay | 1 μM | 3 h | Inhibition of GSK3 phosphorylation | 25014775 |
| K562 | Function Assay | 1 μM | 3 h | Inhibition of P70S6K phosphorylation | 25014775 |
| K562 | Function Assay | 1 μM | 3 h | Inhibition of Akt phosphorylation | 25014775 |
| U266 | Growth Inhibition Assay | 40 μM | 48 h | 79.5% inhibition rate | 25339332 |
| HuT78 | Growth Inhibition Assay | 10 μM | 72 h | does not induce apoptosis | 22801959 |
| MJ | Growth Inhibition Assay | 10 μM | 72 h | does not induce apoptosis | 22801959 |
| DERL7 | Growth Inhibition Assay | 10 μM | 72 h | does not induce apoptosis | 22801959 |
| L1236 | Function Assay | 10 μM | 2 h | Inhibition of Akt phosphorylation | 22210877 |
| L428 | Function Assay | 10 μM | 2 h | Inhibition of Akt phosphorylation | 22210877 |
| L591 | Function Assay | 10 μM | 2 h | Inhibition of Akt phosphorylation | 22210877 |
| KMH-2 | Function Assay | 10 μM | 2 h | Inhibition of Akt phosphorylation | 22210877 |
| L1236 | Function Assay | 5 μM | 24 h | Blocks secretion of the CCL5 | 22210877 |
| L591 | Function Assay | 5 μM | 24 h | Blocks secretion of the CCL5 | 22210877 |
| L1236 | Apoptosis Assay | 5 μM | 24 h | Induction of apoptosis | 22210877 |
| L591 | Apoptosis Assay | 5 μM | 24 h | Induction of apoptosis | 22210877 |
| U-87MG | Function Assay | 100 nM | 24 h | Inhibition of cell migration | 22079609 |
| SW1783 | Function Assay | 100 nM | 24 h | Inhibition of cell migration | 22079609 |
| U-87MG | Function Assay | 5 μM | 24 h | Inhibition of Akt phosphorylation substantially | 22079609 |
| SW1783 | Function Assay | 5 μM | 24 h | Inhibition of Akt phosphorylation substantially | 22079609 |
| U-373MG | Function Assay | 5 μM | 24 h | Inhibition of Akt phosphorylation substantially | 22079609 |
| SK-MG3 | Function Assay | 5 μM | 24 h | Inhibition of Akt phosphorylation substantially | 22079609 |
| SU-DHL-5 | Function Assay | 1 μM | 24 h | Induction of apoptosis | 20959606 |
| WSU-NHL | Function Assay | 1 μM | 24 h | Induction of apoptosis | 20959606 |
| CCRF-SB | Function Assay | 1 μM | 24 h | Induction of apoptosis | 20959606 |
| INA-6 | Function Assay | 5 μM | 6 h | Inhibition of PI3K/Akt and ERK pathway | 20505158 |
| LB | Function Assay | 5 μM | 6 h | Inhibition of PI4K/Akt and ERK pathway | 20505158 |
| MOLM14 | Antitumor assay | 100 mg/kg | 14 days | Antitumor activity against human MOLM14 cells xenografted in nu/nu mouse assessed as tumor growth inhibition at 100 mg/kg, po administered daily via gavage dosed for 14 days and measured daily during compound dosing relative to control | 30053721 |
| MOLM14 | Antitumor assay | 100 mg/kg | 14 days | Antitumor activity against human MOLM14 cells xenografted in nu/nu mouse assessed as induction of apoptosis at 100 mg/kg, po administered daily via gavage dosed for 14 days and measured daily during compound dosing by TUNEL based assay | 30053721 |
| MOLM14 | Antitumor assay | 100 mg/kg | 14 days | Antitumor activity against human MOLM14 cells xenografted in nu/nu mouse assessed as inhibition of tumor proliferation 100 mg/kg, po administered daily via gavage dosed for 14 days and measured daily during compound dosing by Ki-67 labelling based immunoh | 30053721 |
| MOLM14 | Antiproliferative assay | 3 days | Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo assay, IC50 = 3.6 μM. | 27774127 | |
| MV4-11 | Antiproliferative assay | 3 days | Antiproliferative activity against human MV4-11 cells after 3 days by CellTiter-Glo assay, IC50 = 6.3 μM. | 27774127 | |
| Jurkat | Antiproliferative assay | 3 days | Antiproliferative activity against human Jurkat cells after 3 days by CellTiter-Glo assay, IC50 = 7.9 μM. | 27774127 | |
| Loucy | Antiproliferative assay | 3 days | Antiproliferative activity against human Loucy cells after 3 days by CellTiter-Glo assay, IC50 = 8.4 μM. | 27774127 | |
| MOLT4 | Antiproliferative assay | 3 days | Antiproliferative activity against human MOLT4 cells after 3 days by CellTiter-Glo assay, IC50 = 10.6 μM. | 27774127 | |
| SUDHL6 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SUDHL6 cells measured after 72 hrs by alamar blue assay, IC50 = 0.1176 μM. | 27846451 | |
| SU-DHL4 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SU-DHL4 cells measured after 72 hrs by alamar blue assay, IC50 = 1.6 μM. | 27846451 | |
| Pfeiffer | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Pfeiffer cells measured after 72 hrs by alamar blue assay, IC50 = 6.8 μM. | 27846451 | |
| KARPAS422 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KARPAS422 cells measured after 72 hrs by alamar blue assay, IC50 = 8.1 μM. | 27846451 | |
| Sf21 | Function assay | 30 mins | Inhibition of N-terminal His6-tagged recombinant full-length human PI3K p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2/ATP as substrate after 30 mins by TR-FRET assay, IC50 = 3.7 μM. | 28106991 | |
| Sf21 | Function assay | 30 mins | Inhibition of N-terminal His6-tagged recombinant full-length human PI3K p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2/ATP as substrate after 30 mins by TR-FRET assay, IC50 = 3.7 μM. | 28106991 | |
| RPMI8266 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human RPMI8266 cells after 72 hrs by MTT assay, IC50 = 0.00549 μM. | 28325601 | |
| Raji | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Raji cells after 72 hrs by MTT assay, IC50 = 0.00995 μM. | 28325601 | |
| SUDHL6 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SUDHL6 cells after 72 hrs by CCK8 assay, IC50 = 0.65 μM. | 29534936 | |
| RPMI8226 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay, IC50 = 5.49 μM. | 29534936 | |
| Raji | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Raji cells after 72 hrs by MTT assay, IC50 = 9.95 μM. | 29534936 | |
| MOLM13 | Growth inhibition assay | 72 hrs | Growth inhibition of human MOLM13 cells after 72 hrs by CellTiter-Glo luminescent assay, GI50 = 1.7 μM. | 30053721 | |
| MOLM14 | Growth inhibition assay | 72 hrs | Growth inhibition of human MOLM14 cells after 72 hrs by CellTiter-Glo luminescent assay, GI50 = 6.4 μM. | 30053721 | |
| CLL PBMCs | Growth Inhibition Assay | IC50=2.9 nM | 25917267 | ||
| MEC1 | Growth Inhibition Assay | IC50=20.4 μM | 25999352 | ||
| B-cells | Function assay | Inhibition of PI3Kdelta in B-cells by proliferation assay, IC50 = 0.0061 μM. | 22924688 | ||
| insect cells | Function assay | Inhibition of recombinant human full length His-tagged PI3Kgamma expressed in insect cells, IC50 = 0.089 μM. | 27846451 | ||
| insect cells | Function assay | Inhibition of recombinant human full length His-tagged PI3Kbeta expressed in insect cells, IC50 = 0.565 μM. | 27846451 | ||
| KARPAS422 | Growth inhibition assay | Growth inhibition of human KARPAS422 cells by CCK8 assay, GI50 = 0.68 μM. | 28835805 | ||
| Pfeiffer | Growth inhibition assay | Growth inhibition of human Pfeiffer cells by CCK8 assay, GI50 = 0.74 μM. | 28835805 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| SU-DHL6 | Growth inhibition assay | Growth inhibition of human SU-DHL6 cells by CellTiter-Glo assay, GI50 = 0.042 μM. | 29601991 | ||
| 點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Idelalisib (CAL-101)是選擇性p110δ抑制劑，在無(wú)細(xì)胞試驗(yàn)中IC50為 2.5 nM；對(duì) p110δ 表現(xiàn)出的選擇性是對(duì) p110α/β/γ 的 40 到 300 倍，對(duì)p110δ的選擇性是對(duì) C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 還可誘導(dǎo)自噬。 | ||||
|---|---|---|---|---|---|
| 特性 | Calistoga 暗示 CAL-101治療血液惡性腫瘤可能有更廣泛的應(yīng)用價(jià)值。 | ||||
| 靶點(diǎn) |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | CAL-101 對(duì)p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜堿細(xì)胞特定阻斷Fc?R1 p110δ調(diào)節(jié)的 CD63表達(dá)，EC50 為8 nM。與急性髓性白血病(AML) 和骨髓增生性腫瘤(MPN) 細(xì)胞相比，CAL-101 作用于B-cell急性淋巴細(xì)胞白血病(B-ALL)和慢性淋巴細(xì)胞白血病(CLL) 細(xì)胞時(shí)顯示更強(qiáng)的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB細(xì)胞，降低pAktS473, pAktT308, 和下游靶點(diǎn)S6， EC50為0.1到1.0 μM。 [1] CAL-101 作用于CLL細(xì)胞，誘導(dǎo)選擇性細(xì)胞毒性，不是通過(guò)突變狀態(tài)或間期細(xì)胞遺傳學(xué),主要通過(guò)caspase依賴機(jī)制。與正常B細(xì)胞相比，CAL-101作用于CLL 細(xì)胞優(yōu)先產(chǎn)生細(xì)胞毒性，和LY294002相比，作用于其他造血細(xì)胞不會(huì)產(chǎn)生毒性。CAL-101 作用于T 細(xì)胞和天然殺傷細(xì)胞 缺乏直接的細(xì)胞毒性潛能。CAL-101抑制炎癥細(xì)胞因子的產(chǎn)生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活誘導(dǎo)的細(xì)胞因子,如CD40L。CAL-101 也抗CD40L調(diào)節(jié)的CLL細(xì)胞存活。[2] CAL-101 作用于L1236和L591細(xì)胞, 誘導(dǎo)細(xì)胞在G1期積累，在S期下降，說(shuō)明 CAL-101可以作為治療霍杰金淋巴瘤(HL)的一種新策略。[3] |
|||
|---|---|---|---|---|
| 激酶實(shí)驗(yàn) | PI3K實(shí)驗(yàn) | |||
| 用全CLL和正常B細(xì)胞溶解物進(jìn)行PI3K實(shí)驗(yàn)。 進(jìn)行PI3K ELISA 實(shí)驗(yàn)。全細(xì)胞抽提物加到PI(4,5)P2 底物和反應(yīng) buffer（包含 ATP)的混合物中，在室溫下溫育。加入 PI(3,4,5)P3 探測(cè)器和 EDTA混合，反應(yīng)終止，在室溫下溫育1小時(shí)?；旌衔镛D(zhuǎn)移到PI3K ELISA板上，再溫育1小時(shí)。 沖洗反應(yīng)板，然后和第二探測(cè)器再溫育30分鐘。再次沖洗反應(yīng)板, 加入3,3′,5,5′-四甲基聯(lián)苯胺溶液 ，反應(yīng)5分鐘，加入H2SO4 終止反應(yīng)。在450納米處讀數(shù)。 | ||||
| 細(xì)胞實(shí)驗(yàn) | 細(xì)胞系 | CLL B 細(xì)胞或健康志愿者的T細(xì)胞或NK細(xì)胞 | ||
| 濃度 | 0.01-100 μM | |||
| 孵育時(shí)間 | 48小時(shí) | |||
| 方法 | 進(jìn)行MTT實(shí)驗(yàn)測(cè)定細(xì)胞毒性。1×105個(gè)細(xì)胞和CAL-101一起溫育。加入MTT試劑, 再次溫育20小時(shí)，然后用溶于PBS的硫酸魚(yú)精蛋白沖洗。加入DMSO, 用分光光度計(jì)在540納米處測(cè)定吸光度。使用膜聯(lián)蛋白/PI液式細(xì)胞計(jì)檢查在不同時(shí)間點(diǎn)測(cè)定細(xì)胞存活力，分析數(shù)據(jù)。每個(gè)樣本至少計(jì)數(shù)104個(gè)細(xì)胞。以全部陽(yáng)性細(xì)胞與未處理細(xì)胞之比百分?jǐn)?shù)的形式來(lái)表示實(shí)驗(yàn)結(jié)果。加入100 μM Z-VAD檢測(cè)caspase-依賴的細(xì)胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α測(cè)定存活信號(hào), 或者共培養(yǎng)在纖連蛋白或 HS-5 細(xì)胞系基質(zhì)包被的板上。 基質(zhì)共培養(yǎng) 在75cm2培養(yǎng)瓶 (80%-100% 融合率) 培養(yǎng)24 小時(shí)，然后加入CLL細(xì)胞。 |
|||
| 實(shí)驗(yàn)圖片 | 檢測(cè)方法 | 檢測(cè)指標(biāo) | 實(shí)驗(yàn)圖片 | PMID |
| Western blot | PUMA / p53 Bim / Bcl-xl / Bid / Mcl-1 p-p65 p-AKT / AKT Cleaved caspase 3 / Cleaved caspase 9 Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax p-FoxO3a / FoxO3a Akt(T308) / PDK1(S241) / GSK-3β(S9) |
|
28008149 | |
| Growth inhibition assay | Cell viability Cell viability |
|
28008149 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03582098 | Completed | Chronic Lymphocytic Leukaemia |
Gilead Sciences |
September 12 2018 | -- |
| NCT03151057 | Terminated | B Cells-Tumors|B Cell Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Gilead Sciences |
July 31 2018 | Phase 1 |
| NCT03568929 | Completed | Follicular Non-Hodgkin''s Lymphoma Refractory |
Gilead Sciences |
May 25 2018 | -- |
化學(xué)信息&溶解度
| 分子量 | 415.42 | 分子式 | C22H18FN7O |
| CAS號(hào) | 870281-82-6 | SDF | Download Idelalisib (CAL-101) SDF |
| Smiles | CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 | ||
| 儲(chǔ)存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 83 mg/mL ( (199.79 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開(kāi)封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計(jì)算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動(dòng)物體內(nèi)配方計(jì)算器 | ||||
實(shí)驗(yàn)計(jì)算
摩爾濃度計(jì)算器
動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）
第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過(guò)程中的損耗，建議多配一只動(dòng)物的藥量）
mg/kg
g
μL
只
第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計(jì)算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過(guò)該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購(gòu)、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問(wèn)題，均可以通過(guò)撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。
如果有其他問(wèn)題，請(qǐng)給我們留言。
* 必填項(xiàng)
常見(jiàn)問(wèn)題及建議解決方法
問(wèn)題 1:
What is the recommended dose of CAL-101 and the route of administration for mouse studies?
回答：
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684
Tags: buy Idelalisib (CAL-101) | Idelalisib (CAL-101) supplier | purchase Idelalisib (CAL-101) | Idelalisib (CAL-101) cost | Idelalisib (CAL-101) manufacturer | order Idelalisib (CAL-101) | Idelalisib (CAL-101) distributor
Copyright 2013 Selleck中國(guó). All Rights Reserved.
滬ICP備13045345號(hào)-1滬公網(wǎng)安備 31011502012800號(hào)
